Neurofilament Light Considered as NIV Biomarker for Alzheimer's Disease
By LabMedica International staff writers Posted on 06 May 2019 |
Image: Neurofilaments (red) in cultured rat brain cells (Photo courtesy of Wikimedia Commons).
Results presented in a recently published paper suggested that plasma neurofilament light protein may serve as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD).
Neurofilament light polypeptide (NfL), also known as neurofilament light chain, is a neurofilament protein that in humans is encoded by the NEFL gene. Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and plasma and reflects axonal damage in a wide variety of neurological disorders. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and more recently Huntington's disease.
An international team of investigators examined whether longitudinal plasma NfL levels were associated with other hallmarks of AD such as amyloid plaques and tau phosphorylation. To accomplish this task, they used data from 1583 individuals in the multicenter Alzheimer’s Disease Neuroimaging Initiative study had been conducted from September 2005 through June 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018.
Results revealed that of the included 1583 participants, 716 (45.2%) were women, and the mean age was 73 years; 401 had cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia and increased in all diagnostic groups, with the greatest increase in patients with AD dementia.
The findings suggested that plasma NfL could be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and could be useful to monitor effects in trials of disease-modifying drugs.
The study was published in the April 22, 2019, online addition of the journal JAMA Neurology.
Neurofilament light polypeptide (NfL), also known as neurofilament light chain, is a neurofilament protein that in humans is encoded by the NEFL gene. Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and plasma and reflects axonal damage in a wide variety of neurological disorders. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and more recently Huntington's disease.
An international team of investigators examined whether longitudinal plasma NfL levels were associated with other hallmarks of AD such as amyloid plaques and tau phosphorylation. To accomplish this task, they used data from 1583 individuals in the multicenter Alzheimer’s Disease Neuroimaging Initiative study had been conducted from September 2005 through June 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018.
Results revealed that of the included 1583 participants, 716 (45.2%) were women, and the mean age was 73 years; 401 had cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia and increased in all diagnostic groups, with the greatest increase in patients with AD dementia.
The findings suggested that plasma NfL could be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and could be useful to monitor effects in trials of disease-modifying drugs.
The study was published in the April 22, 2019, online addition of the journal JAMA Neurology.
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders